Servier Articles
European Commission enforcement action in pharmaceutical sector following sector inquiry
31 January 2013
Four new safety referrals evaluated as impact of new pharmacovigilance legislation kicks in, says EMA
2 December 2012
XOMA's perindopril and amlodipine FDC meets primary endpoint in Ph III blood pressure trial
23 November 2012
Servier collaborates with Australia's academia for neurodegenerative disorder research
15 October 2012
EMA backs Protelos and Osseor, but with warnings
19 March 2012
EC closes procedural case against Servier
29 January 2012
XOMA acquires US rights to perindopril franchise
18 January 2012
Third deal with Servier for Vernalis
17 January 2012
BioInvent and Servier ink oncology collaboration
5 January 2012
Servier partners with Canada’s Prognomix on type 2 diabetes research
11 November 2011
Hybrigenics in licensing deal with Servier for oncology and other therapeutic fields
11 October 2011
Servier and Galapagos in 260 million-euro oncology deal
4 October 2011
Intercept Pharma in $163 million deal with Servier for TGR5 program in type 2 diabetes
10 August 2011
XOMA and Lab Servier in deal for multi-indication drug candidate worth a potential $505 million
5 January 2011
Highlights of ESC include strong data on AstraZeneca’s Brilinta and Servier’s Procoralan; ESC guideline for atrial fibrillation
31 August 2010
Osteologix and Servier enter ex-US osteo drug licensing deal worth a potential 42 million euros
3 August 2010
European Commission finds France’s Servier provided misleading and incorrect information
28 July 2010
European academia, biotech and pharma industry join forces to fight diabetes, via IMIDIA project
15 June 2010
European Commission confirms further surprise inspections in the pharmaceutical sector
10 December 2009
Osteologix continues development of NB S101 for osteoporosis
21 October 2009
Servier’s Valdoxan superior to Prozac for severe depression in adults
19 September 2009
Patent protection for key blockbuster depression drugs will drive growth in Europe and Japan, but not USA, says DR report
18 August 2009
Slovenia's Galex records 902% jump in sales
29 May 2009
Sinobiopharma's perindopril approved in China
14 May 2009
Evotec buys Sumit Zebrafish operations
8 May 2009
Servier's agomelatine approved in Europe
2 March 2009
Hybrigenics' 2008 sales increase 22%
9 February 2009
Servier drug improves bone structure vs alendronate
12 January 2009
Indonesia tells drug firms: "invest or go"
8 December 2008
CHMP gives nod to four new drugs at meeting
1 December 2008
UK's NICE issues final guidance on osteoporosis prevention
3 November 2008
Procoralan cuts risk of CV events when added to optimal therapy
8 September 2008
Control of Pierre Fabre goes to Foundation
8 September 2008
Servier plans to invest
14 July 2008
NOD protection with Servier drug combo
12 May 2008
LEEM marks first European Rare Diseases Day
10 March 2008
Teva and Servier plan Hungarian expansions
11 February 2008
France's pharmacists concern over drug costs
21 January 2008
Review of the annual meeting of the ECNP
22 October 2007
Cheap BP drugs could save many type 2 diabetic patients' lives
10 September 2007
Amgen acquires Alantos for $300M
18 June 2007
Bulgarian pharma market grows 18.5%
4 June 2007
Vernalis enters cancer R&D accord with Servier
28 May 2007
Study: Protelos cuts hip fracture risk 43%
21 May 2007
Servier generics unit "not for sale"
21 May 2007
Pres-elect Sarkozy lifts pharma hopes in France
14 May 2007
Presidential campaign trail for France's G5
2 April 2007
ABPI "admonishes" Servier and Shire
26 March 2007
SMC recommends approval of Procoralan
19 March 2007
Poor 2006 for French drugmakers goes on
12 March 2007
Hungarian pharma manufacturers call for conciliatory forum
12 February 2007
French drugmakers' growth declining
22 December 2006
Patent expiries will stem growth of antidepressants market
18 December 2006
First Parallel imports hit French market
18 December 2006
Alantos licenses DPP-4 drug to Servier
13 November 2006
Servier makes $232M investment in Ireland
6 November 2006
Servier to build Russian Rx plant
9 October 2006
ESC angina guidelines advocate If inhibitors
18 September 2006
Sevier sues Krka over perindopril
7 August 2006
Servier extends deal with Tripos
7 August 2006
Japan stock market week to June 12, 2006
19 June 2006
Astellas ends FK481 R&D deal with Servier
5 June 2006
Genfit preparing for listing on Paris Bourse
15 May 2006
UPDATE: ABPI suspends Abbott Labs over hospitality, also raps GSK for breach of undertaking
20 February 2006
Abbott Laboratories suspended from ABPI
20 February 2006
Generics market takes off in France
6 February 2006
Xceleron and Servier accord on drug development
30 January 2006
Servier to adopt Xceleron's microdose technology
12 December 2005
ASCOT redefines treatment of cardiovascular risk in hypertension
12 September 2005
Scotland OKs Xeloda but fears in England/Wales
15 August 2005
- Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- It's official: "obesity is a disease," says AMA
- Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
